Search the database for deliberate release of GM medicinal products
Displaying 1 - 4 of 4
|EU record number
|Company / Sponsor
|Phase I study to assess safety, tolerability and immunogenicity of the hRVFV-4s vaccine in healthy subjects
|Wageningen Bioveterinary Research (Larissa Consortium)
|hRVFV-4s is a four segments human Rift Valley fever virus vaccine, which derives from a natural clone (Clone 13) that lacks 69% of the gene NSs, a major virulence determinant of the virus. The hRVFV-4s vaccine is further attenuated by splitting the M genome segment into two M-type segments.
|Only notified under the "contained use" procedure. Dossier submitted on 24/04/2018.
|A Phase 2a Randomized, Double-blind, Placebo-controlled rial to Assess the safety, Immunogenicity, and Efficacy of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Volunteers
|Bavarian Nordic A/S
|Vaccinia virus Ankara strain expression glycoproteins of different RSV strain (MVA-BN)
|Only notified under the "contained use" procedure. Dossier submitted on 20/08/2015.
|A single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
|Catapult Cell Therapy
|Expression of the Wilms' tumour antigen 1 (WT1)- specific T cell receptor (TCR)
|Phase 1b and Phase 2a clinical trials with an hIL-10-expressing Lactococcus lactis
|Gene coding for the human interleukin-10 (hIL-10)